Related Experiment Videos
Spiramycin: safety in man
J Descotes1, T Vial, D Delattre
1Laboratoire de Pharmacologie, Unité INSERM U80-CNRS UA1177-UCBL Faculté de Médecine Alexis Carrel, Lyon, France.
Abstract:
Spiramycin, a 16-membered lactone ring macrolide, has been in clinical use for the past 15 years with little serious associated toxicity. Gastrointestinal disturbance has usually been mild and no changes in gastrointestinal motility have been noted either experimentally or in humans, in contrast to other macrolides, such as erythromycin. Allergic reactions have been uncommon and mainly restricted to transient skin eruptions. Although liver injury is a possible complication of most macrolide treatments, no conclusive evidence for spiramycin-induced hepatitis is currently available, and, again in contrast to most other macrolides, the lack of drug interactions with spiramycin has been clearly established in biochemical, pharmacokinetic and clinical studies.
Insights
Spiramycin, a macrolide antibiotic, shows a favorable safety profile with minimal gastrointestinal and allergic side effects. Unlike other macrolides, it demonstrates a lack of significant drug interactions and no conclusive evidence of liver injury.
Area of Science:
- Pharmacology
- Clinical Toxicology
- Microbiology
Background:
- Spiramycin is a 16-membered macrolide antibiotic with a 15-year clinical history.
- Macrolide antibiotics, including erythromycin, can cause gastrointestinal disturbances and drug interactions.
- Hepatotoxicity is a potential concern with various macrolide treatments.
Purpose of the Study:
- To evaluate the safety and tolerability of spiramycin in clinical use.
- To compare the adverse effect profile of spiramycin with other macrolides.
- To investigate the potential for drug interactions and hepatotoxicity associated with spiramycin.
Main Methods:
- Review of clinical data and adverse event reports for spiramycin.
- Experimental studies on gastrointestinal motility.
- Biochemical and pharmacokinetic analyses to assess drug interactions.
- Clinical studies to confirm drug interaction profiles.
Main Results:
- Spiramycin exhibits minimal serious toxicity over 15 years of clinical use.
- Gastrointestinal disturbances are typically mild and do not affect motility, unlike erythromycin.
- Allergic reactions are uncommon, primarily transient skin eruptions.
- No conclusive evidence of spiramycin-induced hepatitis exists.
- Spiramycin has a well-established lack of drug interactions.
Conclusions:
- Spiramycin is a well-tolerated macrolide antibiotic with a low incidence of adverse effects.
- Its safety profile is distinguished by minimal gastrointestinal impact, rare allergic reactions, absence of significant drug interactions, and no confirmed hepatotoxicity.
- Spiramycin represents a safer alternative within the macrolide class, particularly for patients at risk of drug interactions or gastrointestinal upset.